Evolent Health stock
EVHNYSEEvolent Health, Inc., HealthcareISIN US30050B1017
44Score 44 out of 100, Weak
Price and trend
88 / 100
Price history
+7.2% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 23% below its 52-week high. Largest decline in 11 years: 95% (September 2022 to March 2026).
Chart figures for advanced users
- SMA 50$4.21
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.91
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.17
- The lowest closing price of the last twelve months.
- Resistance$6.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Evolent Health, Inc. belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $536.53M, is number 21 of 24 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.88B (down 26.6% year on year) and a loss of $534.51M.
- For fiscal 2026, analysts expect on average revenue of $2.64B (up 40.7%) and adjusted earnings per share of $0.20 (up 123.2%).
Show more
- MEQIRI Score 44 out of 100 (Weak): rank 470 of 702 in Healthcare, median 53.
- Our model puts fair value at $10.51, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 44.5% a year through 2028 (estimates from 7 analysts).Growth 67
Weaknesses
- DilutionShare count up 34% since 2020.Capital allocation 18
- High debtDebt 2.61 times equity (latest quarter), Medical (Healthcare Information Services) median 0.34.Stability 23
- Loss-makingLoss of $507.69M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $7.01 and expensive above $21.03 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 12.8%. At 13.8% the fair value would be $9.25, at 11.8% it would be $12.11.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.1% on the twelve months before. Revenue has grown strongly since 2015, at around 34% per year. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 15%, operating 0%, net −28%. Last 12 months: net −22%. From 2015 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 5 Nov 2026EPS reported $0.06 (expected $0.06)in line with expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 18.0% since 15 Oct 2026.
- Earnings per share
- $0.20+18.0%
- Revenue
- $2.64B+0.2%
- Earnings per share
- $0.37+4.4%
- Revenue
- $3.31B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +28.2%2026 revenue guidance raised to $2.6 billion to $2.7 billion (previously $2.4 billion to $2.6 billion), with the adjusted EBITDA midpoint lifted by narrowing the range to $120 million to $135 million.
“Given our performance in the first half of the year and our current visibility into the remainder of 2026, we're increasing our full year revenue guidance range to $2.6 billion to $2.7 billion and increasing the midpoint of our adjusted EBITDA guidance by narrowing the range to $120 million to $135 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $329,460 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- McCarthy Daniel JosephSale
26 Aug 2026, PRESIDENT
- Shares
- 65,892
- Price
- $5.00
- Value
- $329,460
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Evolent Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- HealthStreamHSTM $865.56M61
- PhreesiaPHR $783.33M54
- SOPHiA GENETICSSOPH $669.1M49
- RaySearch LaboratoriesRAY-B.ST $587.44M67
- NRC HealthNRC $565.34M59
- GPIGPI.MI $481.45M44
- CarlsmedCARL $474.09M46
- ClaritevCTEV $459.31M42
ETFs that hold Evolent Health
Held by 4 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.60% | 0.68% | €5.31M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.04% | 0.40% | €1.5B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
Show 1 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2016)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.